RNACSelecta Biosciences Inc
RNAC
Selecta Biosciences Inc7,725
Mkt Cap
$172.57MVolume
106,532.0052W High
$16.6252W Low
$5.98PE Ratio
-1.30RNAC Fundamentals
Price
$6.51Prev Close
$6.57Open
$6.5350D MA
$7.26Beta
1.81Avg. Volume
129,193.46EPS (Annual)
-$5.02P/B
-1.34Rev/Employee
$37,293.33$74.80
Earnings Recap
Cartesian Therapeutics, Inc. expects its existing cash, cash equivalents, and restricted cash of $126.9M as of December 31, 2025, to fund operating expenses and capital expenditures for at least the next 12 months.
Bullish
Cartesian Therapeutics, Inc. shows promise with Descartes-08's positive 12-month Phase 2b MG data, key FDA designations, and a proprietary mRNA cell therapy platform enabling outpatient administration without pre-treatment chemotherapy.
Bearish
Cartesian Therapeutics, Inc. faces significant losses and funding needs, an unproven mRNA technology with clinical trial risks, and substantial competition, further impacted by a $56.7M impairment charge on its SLE asset.